It’s the fist time I heard of a European Biotech company clinically co-operating with a country in the Arabic gulf… 

Dilaforette_logo

That’s why I was curious to interview Christina Herder, the CEO of the Stockholm-based Dilaforette, which launched a Phase II trial in co-operation with Bahrain and the rest of the Emirates.

Dilaforette, as many Swedish Biotechs, started out from the Karolinska Institute and is now one of the portfolio companies of Karolinska Development (see the interview of the CIO here). The company is tackling Sickle Cell Disease with a small molecule drug (Sevuparin) and is currently undergoing a Phase II with Orphan drug designation.

The interview is about this last development as well as the history of the company and how Herder perceives the Swedish Biotech ecosystem. Here’s a teaser: ‘the Swedish market is just too small, we have to go international‘.


Here’s the video shot at BIO-Europe Spring 2016 in Stockholm…


Feature Image Credit: Philip Hemme and Christina Herder in Stockholm (available under CC 3.0 License by Labiotech.eu)
Previous post

This 27-year-old Woman is Shaking up the Scientific Publishing Industry

Next post

This Successful Phase III Cancer Drug comes from Sea Squirts

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.